Ksenia A. Guseva

Ksenia A. Guseva

Auto-generated profile, based on publicly available information

Ksenia A. Guseva

Federal State Budgetary Institution “V. A. Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2026 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
IMI.A. Matsueva
I.A. Matsueva
APArtem Paltsev
Artem Paltsev
KGK.A. Guseva
K.A. Guseva
UTUliana A. Tsoy
Uliana A. Tsoy
EGElena Grineva
Elena Grineva
Dopamine agonists are an effective and safe treatment for prolactinomas. However, analysis of recent data has shown that dopamine agonists, including cabergoline, can cause tumor fibrosis and complicate subsequent surgery. Objective. To determine the presence or absence of prolactinoma fibrosis in patients receiving cabergoline before surgery and to evaluate its impact on postoperative outcomes. Material and methods. The study included 58 patients with prolactinoma and preoperative cabergoline therapy who underwent transsphenoidal adenomectomy between January 2018 and March 2025. To identify fibrosis, we analyzed prolactinoma tissue samples regarding connective tissue using Masson’s trichrome staining. Results. Fibrosis in prolactinoma was detected in 18 (31%) patients who received cabergoline. Comparison of patients with prolactinoma fibrosis (group 1, 18 patients) with patients whose prolactinomas did not show fibrosis (group 2, 40 patients) revealed significant differences regarding treatment duration and cabergoline dose (76 vs. 17 months, p<0.001; 3.25 mg/week vs. 2 mg/week, respectively, p=0.049). Resection of fibrous prolactinoma required more time (median 30 min) than non-fibrous prolactinoma (20 min) (p=0.04). The total number of complications was higher in patients with prolactinoma fibrosis (p=0.041). Conclusion. Treatment of prolactinoma with cabergoline can lead to fibrosis, and appropriate probability is associated with duration of preoperative therapy. Cabergoline-induced fibrosis increased duration of resection and number of complications.

21 May 2026 in Translational Medicine
Verified
Journal Article
Closed access
KGKsenia A. Guseva
Ksenia A. Guseva
EGEkaterina Goncharova
Ekaterina Goncharova
IDIrina A. Danilova
Irina A. Danilova
IAIrina V. Antonova
Irina V. Antonova
The article presents two autopsy cases of systemic scleroderma that led to the death of patients, as well as a review of the literature on the etiology and pathogenesis of the disease, with a focus on the development of infectious complications in these cases. Scleroderma is a rare connective tissue disorder, and one of the most common causes of death is infectious complications, including sepsis. The aim of this study was to analyze two clinical cases of systemic scleroderma that resulted in the death of patients. Materials and methods. The results of autopsies of two patients with a diagnosis of systemic sclerosis are presented: a 63-year-old woman and a 59-yearold man. In each case, an autopsy was performed with a macroscopic examination of all organs and tissues. For histological examination, in case 1, samples were taken from the lungs, heart, liver, kidneys, skin, esophagus, small and large intestines, right lumbar muscle, and bodies of the I and III lumbar vertebrae; in case 2, samples were taken from the lungs, heart, liver, kidneys, skin, and esophagus.

2 February 2026 in Russian Neurosurgical Journal named after Professor A. L. Polenov
Verified
Journal Article
Closed access
KGK. A. Guseva
K. A. Guseva
APArtem Paltsev
Artem Paltsev
DGD. O. Grigoreva
D. O. Grigoreva
LMLubov Borisovna Mitrofanova
Lubov Borisovna Mitrofanova
INTRODUCTION . Somatostatin analogues are an indispensable therapeutic agent for the treatment of some types of pituitary adenomas. AIM . morphological assessment of the feasibility of targeted therapy of various pituitary adenomas with somatostatin analogues. MATERIALS AND METHODS . Immunohistochemical study with antibodies to adenohypophysis hormones ACTH, PRL, GH, FSH, LH, TSH and to somatostatin receptors SSTR2 and SSTR5 was performed on surgical material of 72 pituitary adenomas. The prevalence of receptor expression was assessed in points. RESULTS . The average value of SSTR2 expression in the group with zero-cell adenomas was (0.3±0.9) points, and SSTR5 – (0.5±1.1) points. In 83 % of cases, there was no expression of receptors. The average value of SSTR2 expression in corticotropinomas was (1.3±1.0) points, and SSTR5 – (2.1±1.7). In 29 % of cases, there was no expression of these receptors. The average value of SSTR2 expression in mammosomatropinomas was (3.0±1.2) points, and SSTR5 – (3.5±1.0). Moreover, expression of receptors was observed in all cases. The average value of SSTR2 expression in somatotropinomas was (2.4±1.7) points, and SSTR5 – (3.7±0.7). In 19 % of cases, there was no SSTR2 expression, and in 13 %, there was no SSTR5 expression. In the group with prolactinomas, the expression of SSTR2 averaged (0.2±0.7) points, and SSTR5 – (2.2±1.2). In 91 % of cases, SSTR2 expression was not observed, and in 9 % – SSTR5. CONCLUSION . The absence of statistically significant difference in the expression of SSTR2 and SSTR5 in corticotropinomas and mammosomatropinomas substantiates the possibility of the effect of somatostatin analogues with first- and secondgeneration drugs. Statistically significant prevalence of SSTR5 expression in prolactinomas and somatotropinomas determines the preferable use of pasireotide. The absence or low expression of SSTR2 and SSTR5 in zero-cell adenomas precludes the possibility of successful use of somatostatin analogues.